{"id":"W2098775844","doi":"10.1056/nejmoa0910383","title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","year":2011,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2775,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta","funders":"U.S. Army Medical Research and Development Command; National Cancer Institute; Genentech; Sanofi; Eli Lilly and Company; California Breast Cancer Research Program; GlaxoSmithKline; Amgen","keywords":"Trastuzumab; Medicine; Anthracycline; Internal medicine; Regimen; Docetaxel; Carboplatin; Breast cancer; Oncology; Cardiotoxicity; Adjuvant; Cancer; Chemotherapy; Surgery; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001163307,0.0001813685,0.000429489,0.000154084,0.0001334813,0.0002103996,0.0002009633,0.0002473008,0.0008360354],"category_scores_gemma":[0.001307852,0.00006882218,0.0001690013,0.0002810704,0.0001789658,0.000109069,0.0001794593,0.0003739279,0.00009968154],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003495507,"about_ca_system_score_gemma":0.0004155653,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002586246,"about_ca_topic_score_gemma":0.0005661273,"domain_scores_codex":[0.9996189,0.0002293155,0.00002924572,0.00002741294,0.00005624786,0.00003886163],"domain_scores_gemma":[0.9996713,0.0001538735,0.00006510439,0.0000216371,0.00002113566,0.00006705173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1766195,0.005950272,0.1232935,0.001955932,0.0006070483,0.002430128,0.0002476077,0.006026058,0.02444026,0.0009064924,0.004320547,0.6532027],"study_design_scores_gemma":[0.1433366,0.3184141,0.3670387,0.001219455,0.003499556,0.0128575,0.0002659805,0.01481479,0.0361521,0.004037728,0.09830144,0.00006205084],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841301,0.01307201,0.0004073814,0.0003222886,0.00007165442,0.0002002726,0.00008855273,0.000009574655,0.001698173],"genre_scores_gemma":[0.9940895,0.004275445,0.0004230076,0.0001962541,0.0001042976,0.0001846961,0.0001957288,0.000002022789,0.0005290947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001163307,"threshold_uncertainty_score":0.006152213,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0562133101311759,"score_gpt":0.3561151897078348,"score_spread":0.2999018795766589,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}